247 related articles for article (PubMed ID: 37382944)
21. Discriminating Interpatient Variabilities of RAS Gene Variants for Precision Detection of Thyroid Cancer.
Fu G; Chazen RS; MacMillan C; Witterick IJ
JAMA Netw Open; 2024 May; 7(5):e2411919. PubMed ID: 38758552
[TBL] [Abstract][Full Text] [Related]
22. Association of Bethesda category and molecular mutation in patients undergoing thyroidectomy.
Mascarella MA; Peeva M; Forest VI; Pusztaszeri MP; Avior G; Tamilia M; Mlynarek AM; Hier MP; Payne RJ
Clin Otolaryngol; 2022 Jan; 47(1):75-80. PubMed ID: 34510770
[TBL] [Abstract][Full Text] [Related]
23. Repeat Fine-Needle Aspiration With Molecular Analysis in Management of Indeterminate Thyroid Nodules.
Papazian MR; Dublin JC; Patel KN; Oweity T; Jacobson AS; Brandler TC; Givi B
Otolaryngol Head Neck Surg; 2023 Apr; 168(4):738-744. PubMed ID: 35412868
[TBL] [Abstract][Full Text] [Related]
24. BRAF
Chen H; Song A; Wang Y; He Y; Tong J; Di J; Li C; Zhou Z; Cai X; Zhong D; Da J
Cancer Med; 2022 Jan; 11(1):40-49. PubMed ID: 34851044
[TBL] [Abstract][Full Text] [Related]
25. BRAF
Choi JH; Yu HW; Lee JK; Kim W; Choi JY; Na HY; Park SY; Ahn CH; Moon JH; Choi SI; Lee HY; Lee WW; Cha W; Jeong WJ
World J Surg Oncol; 2023 Feb; 21(1):49. PubMed ID: 36804879
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of the Molecular Landscape of Pediatric Thyroid Nodules and Use of a Multigene Genomic Classifier in Children.
Gallant JN; Chen SC; Ortega CA; Rohde SL; Belcher RH; Netterville JL; Baregamian N; Wang H; Liang J; Ye F; Nikiforov YE; Nikiforova MN; Weiss VL
JAMA Oncol; 2022 Sep; 8(9):1323-1327. PubMed ID: 35679040
[TBL] [Abstract][Full Text] [Related]
27. Unique Molecular Signatures Are Associated with Aggressive Histology in Pediatric Differentiated Thyroid Cancer.
Mollen KP; Shaffer AD; Yip L; Monaco SE; Huyett P; Viswanathan P; Witchel SF; Duvvuri U; Simons JP
Thyroid; 2022 Mar; 32(3):236-244. PubMed ID: 34915753
[No Abstract] [Full Text] [Related]
28. Facilitation of Definitive Cancer Diagnosis With Quantitative Molecular Assays of BRAF V600E and TERT Promoter Variants in Patients With Thyroid Nodules.
Fu G; Chazen RS; Monteiro E; Vescan A; Freeman JL; Witterick IJ; MacMillan C
JAMA Netw Open; 2023 Jul; 6(7):e2323500. PubMed ID: 37505499
[TBL] [Abstract][Full Text] [Related]
29. Significance of BRAF V600E Mutation and Cytomorphological Features for the Optimization of Papillary Thyroid Cancer Diagnostics in Cytologically Indeterminate Thyroid Nodules.
Beiša A; Kvietkauskas M; Beiša V; Stoškus M; Ostanevičiūtė E; Jasiūnas E; Griškevičius L; Šeinin D; Šileikytė A; Strupas K
Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):247-254. PubMed ID: 29566402
[TBL] [Abstract][Full Text] [Related]
30. Cytological features and nuclear scores: Diagnostic tools in preoperative fine needle aspiration of indeterminate thyroid nodules with RAS or BRAF K601E mutations?
Ravella L; Lopez J; Descotes F; Giai J; Lapras V; Denier ML; Borson-Chazot F; Lifante JC; Decaussin-Petrucci M
Cytopathology; 2021 Jan; 32(1):37-44. PubMed ID: 32803788
[TBL] [Abstract][Full Text] [Related]
31. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
Li J; Liang J; Zhao T; Lin Y
Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
[TBL] [Abstract][Full Text] [Related]
32. A five-gene panel refines differential diagnosis of thyroid nodules.
Lu SY; Chen YC; Zhu CF; Chen J; Zhou QY; Zhang MM; Zhang QY; Lu M; Yang L; Wu J; Zhao SX; Song HD; Ye XP
J Clin Lab Anal; 2021 Sep; 35(9):e23920. PubMed ID: 34318534
[TBL] [Abstract][Full Text] [Related]
33. Outcomes of Indeterminate Thyroid Nodules Managed Nonoperatively after Molecular Testing.
Zhu CY; Donangelo I; Gupta D; Nguyen DT; Ochoa JE; Yeh MW; Livhits MJ
J Clin Endocrinol Metab; 2021 Mar; 106(3):e1240-e1247. PubMed ID: 33394039
[TBL] [Abstract][Full Text] [Related]
34. ThyroSeq overview on indeterminate thyroid nodules: An institutional experience.
Sirotnikov S; Griffith CC; Lubin D; Zhang C; Saba NF; Li D; Kornfield A; Chen A; Shi Q
Diagn Cytopathol; 2024 Jul; 52(7):353-361. PubMed ID: 38554032
[TBL] [Abstract][Full Text] [Related]
35. Multiple Mutations Detected Preoperatively May Predict Aggressive Behavior of Papillary Thyroid Cancer and Guide Management--A Case Report.
Shrestha RT; Karunamurthy A; Amin K; Nikiforov YE; Caramori ML
Thyroid; 2015 Dec; 25(12):1375-8. PubMed ID: 26355276
[TBL] [Abstract][Full Text] [Related]
36. Single Institution Experience with Afirma and Thyroseq Testing in Indeterminate Thyroid Nodules.
Gortakowski M; Feghali K; Osakwe I
Thyroid; 2021 Sep; 31(9):1376-1382. PubMed ID: 33764195
[No Abstract] [Full Text] [Related]
37. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
Llamas-Olier AE; Cuéllar DI; Buitrago G
Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
[TBL] [Abstract][Full Text] [Related]
38. BRAF
Cao J; Chen B; Zhu X; Sun Y; Li X; Zhang W; Wang X
Endocrine; 2024 Apr; 84(1):160-170. PubMed ID: 37851243
[TBL] [Abstract][Full Text] [Related]
39. RAS mutations in indeterminate thyroid nodules are predictive of the follicular variant of papillary thyroid carcinoma.
An JH; Song KH; Kim SK; Park KS; Yoo YB; Yang JH; Hwang TS; Kim DL
Clin Endocrinol (Oxf); 2015 May; 82(5):760-6. PubMed ID: 25109485
[TBL] [Abstract][Full Text] [Related]
40. Predictive factors for nodal recurrence in differentiated thyroid cancers.
Kaur J; Nadarajan A; Janardhan D; George NA; Thomas S; Varghese BT; Krishna J
Cancer Treat Res Commun; 2023; 36():100728. PubMed ID: 37336036
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
